Researchers investigated the binding properties of several hepatitis C drugs to determine how well they inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce. Inhibiting, or blocking, the protease from functioning is vital to stopping the virus from spreading in patients with COVID-19.